Chronic Hepatitis B Infection - 26/04/12
, Robert Gish, MDRésumé |
The management of chronic hepatitis B virus (HBV) infection requires understanding the natural history of the disease as well as the risks, benefits, and limitations of the therapeutic options. This article covers the principles governing when to start antiviral therapy, discusses recent advances using hepatitis B surface antigen quantification to better define various phases of infection, describes the use of HBV core, precore, and viral genotyping as well as host IL28B genotyping to predict response to interferon therapy, and reports on the management of HBV in 3 special populations (pregnancy, postliver transplantation, and in the setting of chemotherapy or immunosuppression).
Le texte complet de cet article est disponible en PDF.Keywords : Hepatitis B virus, HBV genotype, HBsAg quantification, Mother-to-child transmission, Liver transplantation
Plan
| Financial disclosures: Alexander Kuo has nothing to disclose. |
|
| Robert Gish has relevant consulting relationships with Roche/Genentech, Gilead, BMS. All research, consulting, and promotional fees are placed in a UCSD fund for research and education. |
Vol 16 - N° 2
P. 347-369 - mai 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
